ストックスクリーナーアプリを入手
111.04
2.70%
2.92
アフターアワーズ：
112.22
1.18
+1.06%
前日終値:
$108.12
開ける：
$106.02
24時間の取引高:
1.05M
Relative Volume:
0.82
時価総額：
$7.35B
収益：
-
当期純損益:
$-116.25M
株価収益率:
-46.44
EPS:
-2.3912
ネットキャッシュフロー:
$-91.19M
1週間 パフォーマンス:
+12.37%
1か月 パフォーマンス:
+26.95%
6か月 パフォーマンス:
+244.74%
1年 パフォーマンス:
+640.27%
1日の値動き範囲:
$105.10
$111.37
1週間の範囲:
$95.50
$111.37
52週間の値動き範囲:
$14.08
$111.37
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Compare ORKA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
111.04 | 7.11B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Piper Sandler | Overweight |
| 2025-11-13 | 開始されました | Jefferies | Buy |
| 2025-10-27 | 開始されました | Guggenheim | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-10-11 | 開始されました | Stifel | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | Leerink Partners | Outperform |
| 2024-09-16 | 開始されました | TD Cowen | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2018-02-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 開始されました | Dawson James | Buy |
すべてを表示
Oruka Therapeutics Inc (ORKA) 最新ニュース
Oruka Therapeutics (NASDAQ:ORKA) Cut to "Sell" at Wall Street Zen - marketbeat.com
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock By Investing.com - Investing.com Australia
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock - Investing.com
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m By Investing.com - Investing.com Australia
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock - marketbeat.com
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m - Investing.com
Oruka Therapeutics Insider Sold Shares Worth $5,641,409, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Insider Sold Shares Worth $1,066,572, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics stock hits 52-week high at 109.56 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics stock hits 52-week high at 109.56 USD - Investing.com
Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA - marketbeat.com
Sei Investments Co. Raises Position in Oruka Therapeutics, Inc. $ORKA - marketbeat.com
Oruka Therapeutics (ORKA) On Its Earnings Miss And Whether The Valuation Still Holds - Sahm
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180 - moomoo.com
Dimensional Fund Advisors LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA - marketbeat.com
Oruka Therapeutics Inc (ORKA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Oruka Therapeutics (ORKA) Is Up 10.9% After Wider-Than-Expected Q2 Loss From R&D InvestmentHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics' (ORKA) "Buy" Rating Reaffirmed at Guggenheim - marketbeat.com
Oruka Therapeutics' (ORKA) Outperform Rating Reiterated at Wedbush - marketbeat.com
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - marketbeat.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighStill a Buy? - marketbeat.com
ORUKA THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $179 FROM $162 - Bitget
Oruka Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Oruka Therapeutics Q2 Loss Widens - marketscreener.com
Oruka Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Oruka Therapeutics Q2 EPS of $(0.55) misses estimates - scanx.trade
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS - marketbeat.com
Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss - marketscreener.com
Oruka Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics reports Q2 2026 results: $1.1B cash; net loss $41.2M in quarter - TradingView
Press Release: Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - moomoo.com
Oruka Therapeutics (ORKA) Earnings Date and Reports 2026 - marketbeat.com
The Manufacturers Life Insurance Company Acquires 11,205 Shares of Oruka Therapeutics, Inc. $ORKA - marketbeat.com
Oruka Therapeutics (NASDAQ:ORKA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
Oruka Therapeutics stock hits 52-week high at 100.11 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics stock hits 52-week high at 100.11 USD - Investing.com
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE - PR Newswire
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighWhat's Next? - MarketBeat
Oruka Therapeutics, Inc. (ORKA) options chain - Yahoo Finance Australia
Oruka Therapeutics (ORKA) Projected to Announce Earnings on Monday - MarketBeat
Oruka Therapeutics Is Priced For PerfectionIt’s Time To Cash Out (NASDAQ:ORKA) - Seeking Alpha
Perceptive Advisors LLC Sells 81,000 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics, Inc. $ORKA Stock Position Increased by Avidity Partners Management LP - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 51% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Remedium Capital Partners LLC Raises Holdings in Oruka Therapeutics, Inc. $ORKA - marketbeat.com
Oruka Therapeutics stock reaches 52-week high at 97.81 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighTime to Buy? - marketbeat.com
Oruka Therapeutics Inc (ORKA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oruka Therapeutics Inc (ORKA) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):